Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Aytu Biopharma (AYTU) Research & Development (2016 - 2025)

Aytu Biopharma (AYTU) has disclosed Research & Development for 12 consecutive years, with $216000.0 as the latest value for Q2 2025.

  • On a quarterly basis, Research & Development fell 79.27% to $216000.0 in Q2 2025 year-over-year; TTM through Dec 2025 was $378000.0, a 85.47% decrease, with the full-year FY2025 number at $1.3 million, down 52.11% from a year prior.
  • Research & Development was $216000.0 for Q2 2025 at Aytu Biopharma, up from $162000.0 in the prior quarter.
  • In the past five years, Research & Development ranged from a high of $4.8 million in Q2 2021 to a low of $162000.0 in Q1 2025.
  • A 5-year average of $1.5 million and a median of $856000.0 in 2023 define the central range for Research & Development.
  • Peak YoY movement for Research & Development: soared 1464.69% in 2021, then plummeted 85.71% in 2023.
  • Aytu Biopharma's Research & Development stood at $4.5 million in 2021, then crashed by 61.79% to $1.7 million in 2022, then plummeted by 69.53% to $521000.0 in 2023, then increased by 0.19% to $522000.0 in 2024, then tumbled by 58.62% to $216000.0 in 2025.
  • Per Business Quant, the three most recent readings for AYTU's Research & Development are $216000.0 (Q2 2025), $162000.0 (Q1 2025), and $522000.0 (Q4 2024).